EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population Pharmacokinetics and Dose Optimization of Valganciclovir and Ganciclovir in Lung Transplant Recipients

Eliška Dvořáčková, Danica Michaličková, Jakub Petrus, Eva Klapková, Alžběta Dutková, Tereza Kotowski, Andrea Zajacová, Elke H J Krekels, Jan Havlin, Robert Lischke, Ondřej Slanař

Medical Principles and Practice · 2025

DOI: 10.1159/000548942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Principles and Practice, 2025. Verfasst von Eliška Dvořáčková und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. Hauptthemen laut MEDLINE: Ganciclovir, Valganciclovir, Lung Transplantation, Antiviral Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The primary goal of this study was to evaluate the pharmacokinetics (PK) of ganciclovir (GCV) and its prodrug valganciclovir (VGCV) in a large cohort of lung transplant recipients. The secondary goal was to determine the probability of target attainment (PTA) for different pharmacokinetic/pharmacodynamic (PK/PD) targets. Subjects and Methods: A population PK analysis was carried out using NONMEM version 7.4.0. In total, 379 GCV concentrations (194 and 185 concentrations sampled after VGCV and GCV administration, respectively) were obtained from 110 patients and were included in the analysis. Monte Carlo simulations were performed to assess PTA for (AUC24h) >50 mg·h/L and AUC24h of 80–120 mg·h/L.

Results

Estimated glomerular filtration rate (eGFR) was found to be the only significant covariate for GCV/VGCV clearance. Standard prophylactic and therapeutic GCV/VGCV dosing regimens lead to underdosing in patients with reduced eGFR values, particularly below 60 mL/min/1.73 m2 for VGCV and 70 mL/min/1.73 m2 for ganciclovir. For patients with higher eGFR levels, PTA levels are higher (21–35% in therapy and 44–50% in prophylaxis), but the PK show substantial variability, making individual dosing difficult.

Conclusions

Standard prophylactic and therapeutic ganciclovir/VGCV dosing regimen leads to underexposure in patients with low eGFR but may be appropriate for patients with higher eGFR values. However, substantial variability in ganciclovir/VGC exposure makes it challenging to achieve efficacy targets in individuals. For this reason, therapeutic drug monitoring (TDM) should be considered. Our model can be integrated into TDM software and, alongside a TDM sample, be used for dosing guidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GanciclovirValganciclovirLung TransplantationAntiviral AgentsHumansMaleMiddle AgedFemaleAdultGlomerular Filtration RateAgedMonte Carlo MethodTransplant RecipientsCytomegalovirus InfectionsDose-Response Relationship, Drug

Stichwörter der Autor:innen

GanciclovirLung transplantationNONMEMPharmacokineticsValganciclovir

Substanzen

GanciclovirValganciclovirAntiviral Agents

Autor:innen und Institutionen

  • Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
  • Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia, danica.michalickova@lf1.cuni.cz.
  • Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czechia.
  • Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czechia.
  • Division of Systems Pharmacology and Pharmacy, Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
  • Certara Inc, Princeton, New Jersey, USA.

Förderung

  • Ministry of Health of Czech Republic

Zitieren

APA

Dvořáčková, E., Michaličková, D., Petrus, J., Klapková, E., Dutková, A., Kotowski, T., Zajacová, A., Krekels, E. H. J., Havlin, J., Lischke, R., & Slanař, O. (2025). Population Pharmacokinetics and Dose Optimization of Valganciclovir and Ganciclovir in Lung Transplant Recipients. Medical Principles and Practice. https://doi.org/10.1159/000548942

Vancouver

Dvořáčková E, Michaličková D, Petrus J, Klapková E, Dutková A, Kotowski T, et al. Population Pharmacokinetics and Dose Optimization of Valganciclovir and Ganciclovir in Lung Transplant Recipients. Medical Principles and Practice. 2025. doi:10.1159/000548942

BibTeX
@article{Dvokov2025,
  author = {Dvořáčková, Eliška and Michaličková, Danica and Petrus, Jakub and Klapková, Eva and Dutková, Alžběta and Kotowski, Tereza and Zajacová, Andrea and Krekels, Elke H J and Havlin, Jan and Lischke, Robert and Slanař, Ondřej},
  title = {Population Pharmacokinetics and Dose Optimization of Valganciclovir and Ganciclovir in Lung Transplant Recipients},
  journal = {Medical Principles and Practice},
  year = {2025},
  doi = {10.1159/000548942}
}
Kostenlos starten →